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Abstract
Background: Simplification of antiretroviral treatment (ART) with darunavir/ritonavir (DRV/r) monotherapy has achieved
sustained suppression of plasma viral load (pVL) in clinical trials; however, its effectiveness and safety profile has not been
evaluated in routine clinical practice.
Methodology/Principal Findings: We performed a retrospective cohort analysis of HIV-1-infected patients who initiated
DRV/r monotherapy once daily with a pVL ,50 copies/mL under ART and at least 1 subsequent follow-up visit in our clinic.
The primary study endpoints were the percentage of patients with virological failure (VF, defined as 2 consecutive pVL.50
copies/mL) at week 48, and time to VF. Other causes of treatment discontinuation and changes in lipid profile were
evaluated up to week 48. Ninety-two patients were followed for a median (IQR) of 73 (57–92) weeks. The median baseline
and nadir CD4+ T-cell counts were 604 (433–837) and 238 (150–376) cells/mm3, respectively. Patients had previously
received a median of 5 (3–9) ART lines and maintained a pVL,50 copies/mL for a median of 76 (32–176) weeks before
initiating DRV/r monotherapy. Nine (9.8%) patients developed VF at week 48; time to VF was 47.1 (IQR: 36.1–47.8) weeks
among patients with VF. Other reasons for changing ART were gastrointestinal disturbances (n=3), rash (n=1), and
impaired CD4 recovery (n=2). Median low-density lipoprotein cholesterol levels increased from 116.1 mg/dL at baseline to
137.3 mg/dL at 48 weeks (p=0.001).
Conclusions/Significance: Treatment simplification with DRV/r monotherapy seems safe and effective in routine clinical
practice. Further research is needed to elucidate the effect of DRV/r monotherapy on cholesterol levels.
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Introduction
Standard-of-care antiretroviral therapy (ART) combines at
least 3 antiretroviral drugs including 2 nucleos(t)ide reverse
transcriptase inhibitors (NRTIs) [1], which may be associated
with toxicity arising from mitochondrial dysfunction [2]. NRTI-
sparing strategies could potentially be as effective as standard
ART, while proving less toxic and preserving future treatment
options.
Monotherapy with protease inhibitors (PIs) is particularly
attractive as an NRTI-sparing strategy, especially in cases of
NRTI-related toxicity or intolerance, and its use in these settings is
still recognized in some guidelines [3,4]. Darunavir/ritonavir
(DRV/r) may be particularly suited for PI monotherapy, because
it has a high genetic barrier, a favorable safety and pharmaco-
kinetic profile, and can be administered once daily [5,6].
Randomized clinical trials have shown that DRV/r monotherapy
as a simplification strategy has similar efficacy to triple ART, with
PLoS ONE | www.plosone.org 1 May 2012 | Volume 7 | Issue 5 | e37442reduced costs and low rates of resistance [7–9]. However, there are
concerns that PI monotherapy might be associated with viral
evolution in the central nervous system or other compartments
with different degrees of penetration, and neurocognitive impair-
ment [10]. Duration of the response to PI monotherapy is unclear,
as are the clinical factors associated with virological failure,
particularly in routine clinical practice, where the efficacy and
safety profile of DRV/r remains largely unknown.
The objective of this study was to evaluate the effectiveness and
safety profile of darunavir/ritonavir (DRV/r) monotherapy as an
NRTI-sparing treatment simplification strategy in HIV-infected
patients with sustained viral suppression in routine clinical
practice.
Methods
Our study sample comprised all consecutive patients who had
initiated DRV/r monotherapy with an HIV-1 RNA load ,50
copies/mL between December 2007 and January 2010. Data were
retrieved from a prospectively compiled database (electronic
medical records). All selected patients were followed until the last
one had completed 48 weeks of follow-up or switched DRV/r
monotherapy. Patients started with DRV/r 900/100 mg once
daily (PrezistaH, Tibotec a division of Janssen-Cilag International,
Beerse, Belgium) and were subsequently switched to DRV/r 800/
100 mg once daily when 400-mg tablets became commercially
available. Patients who had voluntarily discontinued their therapy
or who had been lost to follow-up before completing 48 weeks
were not considered eligible for the analysis, but were included for
the full dataset effectiveness analysis. Demographic and clinical
characteristics, viral load, CD4+ T-cell count, creatinine, liver
enzymes, and fasting lipid profile (total cholesterol, high-density
lipoprotein [HDL] cholesterol, low-density lipoprotein [LDL]
cholesterol, and triglycerides) were recorded when monotherapy
was started (baseline) and every 12 weeks thereafter. In addition,
adverse events leading to discontinuation of treatment and the
development of resistance mutations in those patients whose
DRV/r monotherapy failed were also evaluated. The study was
approved by the ethics committee from Hospital Germans Trias i
Pujol, Badalona, Spain, and it was performed according to the
stipulations of the Declaration of Helsinki (Seoul, 2008). All
patients gave their written informed consent for their medical
information to be used in scientific research.
The primary endpoints of the study were the proportion of
patients whose DRV/r monotherapy had failed at 48 weeks and
their time to virological failure. Virological failure was defined as
an increase in viral load .50 copies/mL at 2 consecutive
determinations. The first date with HIV-1 viral load .50
copies/mL was used to calculate the time to virological failure.
The secondary endpoints were the percentage of patients who
discontinued their treatment for any reason, time to treatment
discontinuation, the overall percentage of patients who maintained
viral suppression, and development of protease resistance muta-
tions. Changes in monotherapy because of toxicity, virological
failure, or other patient- or physician-based reasons were recorded
to calculate the time and treatment discontinuation rate. Factors
associated with virological failure, the percentage of patients with
blips, time to blips, and changes in CD4+ T-cell count, creatinine
level, and liver and fasting lipid profiles were also analyzed.
To assess the impact of DRV/r monotherapy on lipid profile,
we analyzed overall changes in fasting lipid profile from baseline.
We also performed sub-analyses according to previous use of PIs,
tenofovir (TDF), abacavir (ABC), and other NRTIs, and
compared the proportion of patients with dyslipidemia, risk
factors associated with dyslipidemia and lipid-lowering drug use
at baseline and 48 weeks. Dyslipidemia was defined according to
the criteria of the National Cholesterol Education Program
(NCEP) Expert Panel on Detection, Evaluation, and Treatment
of High Blood Cholesterol in Adults (Adult Treatment Panel III)
parameters [11], as well as to the use of lipid-lowering drugs
(ezetimibe, statins, and fibrates).
Variables with a normal distribution were described as mean
(SD) and compared using the t test. Median and interquartile
range (IQR) were employed to describe variables that did not
follow a normal distribution, which were compared by using the
Mann-Whitney non-parametric test. Percentages were compared
using the x
2 square test or an exact binomial test when
Table 1. Baseline characteristics.
a
General cohort (n=92)
Male 62 (67.4)
Age (years)
b 44.4 (38.8–49.9)
HCV co-infection 22 (23.9)
CDC A 76 (82.6)
Time since HIV diagnosis (years)
b 13.2 (8.3–18.1)
Time on treatment (years)
b 10.4 (5.2–14.1)
Type of toxicity
a
Dyslipidemia 20 (21.7)
Kidney 6 (6.5)
Gastrointestinal 5 (5.4)
Central nervous system 2 (2.2)
Liver 1 (1.1)
Peripheral neuropathy 1 (1.1)
Jaundice 1 (1.1)
Others 5 (5.4)
No. of prior ARV regimens
b 5 (3–9)
No. of prior PIs
b 2 (1–3)
ARV drugs use at entry
3TC/FTC 70 (76.1)
TDF 52 (56.5)
ABC 18 (19.6)
Other NRTIs 7 (7.6)
LPV 32 (34.8)
ATV 27 (29.3)
FosAPV 10 (10.9)
DRV 9 (9.8)
SQV 5 (5.4)
NNRTIs 9 (9.8)
RAL 2 (2.2)
CD4+ nadir (cells/mm
3)
b 238 (150–376)
CD4+ T cell count (cells/mm
3)
b 604 (433–837)
aAll values are expressed as No. (%), unless otherwise indicated.
bMedian (interquartile range).
Abbreviations: HCV, hepatitis C virus; CDC, Centers for Disease Control and
Prevention; ARV, antiretroviral; 3TC/FTC, lamivudine/emtricitabine; TDF,
tenofovir; ABC, abacavir; NRTIs, nucleoside reverse transcriptase inhibitors; LPV,
lopinavir; ATV, atazanavir; FosAPV, fosamprenavir; DRV, darunavir; SQV,
saquinavir; NNRTIs, non-nucleoside reverse transcriptase inhibitors; RAL,
raltegravir.
doi:10.1371/journal.pone.0037442.t001
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time to virological failure and to treatment discontinuation. To
evaluate factors associated with virological failure and develop-
ment of dyslipidemia, we performed a Cox regression analysis and
a multivariate logistic regression analysis, respectively. For the
latter, we used only a subset of clinical and pharmacological
variables to adjust the final multivariate model that avoided multi-
collinearity. The hazard ratio and its 95% confidence interval
(95CI) were also calculated. The statistical analysis was performed
using SPSS version 15.0 (SPSS, Chicago, Illinois, USA). Differ-
ences were considered statistically significant at p,0.05.
Results
Baseline Characteristics
We identified 95 patients who were switched from their
conventional ART regimen to DRV/r monotherapy while
maintaining viral suppression. Three patients were excluded from
the analysis because of voluntary interruption. Of the remaining
92 patients, the reasons for switching to DRV/r monotherapy
were reduction in ART-related toxicity in 51 (55.4%) cases and
patients’ request for simplification in 41 (44.6%) cases. The
median (IQR) time to follow-up was 72.5 (57.1–92.3) weeks, and
viral load had remained at ,50 copies/mL for a median of 75.8
(32.4–175.8) weeks before DRV/r monotherapy was started.
Patients had received a median of 5 (3–9) previous ART regimens.
The regimen before monotherapy included lamivudine/emtrici-
tabine (3TC/FTC) in 70 (76.1%) patients, TDF in 52 (56.5%),
lopinavir/ritonavir (LPV/r) in 32 (34.8%), atazanavir/ritonavir
(ATV/r) in 27 (29.3%), another boosted PI in 24 (26.1%), and
non-NRTIs in 9 (9.7%) (Table 1).
Effectiveness
Nine (9.8%) patients experienced virological failure; 4 (44.4%)
of these patients reported poor adherence. Among patients
developing virological failure, the time to virological failure was
47.1 (IQR: 36.1–47.8; 95CI 35.6, 58.5) weeks (Figure 1). Viral re-
suppression was achieved in all cases either by reintroduction of
the previous NRTI backbone (6 cases) or other antiretroviral drugs
(2 cases). The remaining patient achieved viral load suppression
,50 copies/mL on DRV/r monotherapy after adherence
counseling.
Four (4.3%) patients discontinued DRV/r monotherapy
because of adverse effects, and 2 (2.2%) experienced poor recovery
of their CD4+ T-cell count. All these patients had viral load ,50
copies/mL at the moment of DRV/r discontinuation. Virological
suppression was maintained either by different antiretroviral
regimens according to the clinician’s criteria (5 patients) or
reintroduction of the NRTI backbone (1 patient). This last patient
lost the virological suppression, because of voluntary treatment
interruption. Finally, the time to treatment discontinuation for any
reason was 48.5 (IQR: 28.9–53.2; 95CI 44.3, 51.6) weeks
(Figure 1).
Thus, the overall proportion of patients who maintained viral
suppression was 77/92 (83.7%), when only patients whose viral
load was available up to week 48, and when patients who
experienced DRV/r monotherapy discontinuation for any reason
were considered. In the full dataset analysis, including the three
patients with voluntary interruption, 77/95 (81.1%) of subjects
maintained viral suppression. Figure 2 summarizes the effective-
ness results.
Seventeen (18.5%) patients developed blips (HIV RNA ,200
copies/mL) at a median (IQR) of 45 (29.8–49.5) weeks after
DRV/r monotherapy switching. None of these patients experi-
enced virological failure.
Virological failure was not significantly associated to any of the
factors analysed in the univariate or multivariate analysis (i.e.,
presence of blips, gender, age, HCV co-infection, CD4+ nadir,
CD4+ T-cell count at baseline, CDC stage, time since HIV
diagnosis, time on ART, duration of virological suppression, and
number of prior PIs and antiretroviral regimens).
Genotyping
Genotyping data prior to DRV/r monotherapy were available
for 31 (29%) patients. All these patients had viral strains with
polymorphic or minor PI resistance–associated mutations (median
Figure 1. Time to virological failure and to treatment discontinuation in HIV-1-infected patients with DRV/r monotherapy.
Abbreviations: 95% CI, 95% Confidence Interval. This figure shows the time to virological failure and time to treatment discontinuation for any reason
among patients developing treatment failure during the overall follow-up.
doi:10.1371/journal.pone.0037442.g001
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mutations in the protease gene (one patient had L90M, another
D30N, and the third M46I and V82A), which were not associated
with resistance to DRV. None of the patients experienced
virological failure during follow-up.
Figure 2. Summary of effectiveness results. Abbreviations: NRTI, nucleoside reverse transcriptase inhibitors; DRV/r, darunavir/ritonavir; OT,
optimized treatment.
doi:10.1371/journal.pone.0037442.g002
Table 2. Changes in laboratory parameters (n=92).
a
Baseline 24 weeks 48 weeks
P value (Baseline vs
48 weeks)
CD4+ T-cell count (cells/mm
3) 604 (433–837) 629 (468–819) 595 (455.25–769.75) 0.327
Alkaline phosphatase (U/L) 79.5 (66–103) 64 (55–80.25) 64 (54.75–77.25) ,0.001
Aspartate aminotransferase (U/L) 23 (18–31) 22 (16–29) 22 (17–30) 0.352
Alanine aminotransferase (U/L) 22 (17–40.75) 23.5 (14–36.25) 23 (15–40.13) 0.317
Gamma-glutamyl transferase (U/L) 28 (19–38.75) 23 (17.25–36) 24 (18–35.13) 0.008
Creatinine (mg/100 mL) 0.89 (0.76–1.03) 0.89 (0.79–1.01) 0.85 (0.74–0.95) ,0.001
aAll values are expressed as median (interquartile range).
doi:10.1371/journal.pone.0037442.t002
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patients. One patient had no protease gene mutations, whereas the
other 2 showed the following mutations: R41K, I62V, L63P,
I72V/I, V77I, and I93L; and L33V, E35D, D60E, and I64V,
respectively. Although no previous genotypes were available to
establish comparisons, none of these mutations have been
described to be associated with DRV resistance.
Safety
The changes observed in the median values for CD4+ T-cell
count, aspartate aminotransferase, and alanine aminotransferase
at week 48 of follow-up were not significant (p=0.327, p=0.352,
and p=0.317, respectively). However, a significant reduction was
observed in the values for alkaline phosphatase, gamma-glutamyl
transferase, and creatinine (p,0.001, p=0.008, and p,0.001,
respectively) (Table 2).
Four (4.3%) patients discontinued DRV/r monotherapy
because of adverse events and 2 (2.2%) experienced poor recovery
of their CD4+ T-cell count. Adverse events leading to discontin-
uation of DRV/r included diarrhea in 3 patients and skin rash in 1
patient that resolved with voluntary interruption of DRV/r
monotherapy. It is noteworthy that 2 of these 4 patients had not
received PI-based regimens at baseline.
Fasting Lipid Profile
Overall, the median (IQR) LDL-cholesterol level increased
significantly from 116.05 (82.5–137.5) mg/dL at baseline to
137.3 (101.1–155.2) mg/dL at week 48 of follow-up (p=0.001),
with a median increase of 13.0 (25.0 to 35.0) mg/dL. In
addition, triglyceride levels decreased significantly by a median of
217.6 (253.4 to 26.2) mg/dL. There were no significant
changes in total cholesterol (p=0.241) or HDL-cholesterol
(p=0.213) (Figure 3).
A more sensitive analysis based on previously used antiretroviral
drugs showed significant increases in total-cholesterol from 176.1
(150.9–212.8) to 210.6 (178.9–238.9) mg/dL (p=0.001), and
LDL-cholesterol levels from 103.7 (80.2–127.0) to 115.0 (101.1–
155.5) mg/dL (p,0.001) in patients with prior use of TDF. On the
contrary, in patients who had recently received ABC, total
cholesterol at baseline was 205.1 (191.5–230.2) mg/dL and 211.1
(200.1–233.1) mg/dL at week 48 (p=0.985), and LDL-cholesterol
changed from 127.3 (109.2–153.2) to 139.0 (125.7–153.1) mg/dL
(p=0.566). A significant decrease in total cholesterol from 220.6
(192.1–277.6) to 201.2 (182.0–232.2) mg/dL and triglyceride
levels from 208.5 (133.0–348.4) to 142 (100.0–177.0) mg/dL was
observed in patients who had recently received LPV/r (p=0.028
and p,0.001, respectively). In patients who had recently received
ATV/r, a significant increase was observed in total cholesterol
from 185.8 (151.0–216.7) to 213.0 (173.9–249.6) mg/dL
(p=0.016); in patients who had recently received saquinavir, a
significant increase was observed in total cholesterol from 197.3
(170.2–218.6) to 243.8 (203.1–267.0) mg/dL and LDL-cholesterol
levels from 120.3 (90.9–131.5) to 151.0 (116.5–154.7) mg/dL
(p=0.049 and p=0.011, respectively).
According to the ATP III classification [11], there were no
significant changes in the percentage of patients with different cut-
off levels for cholesterol (total, LDL, and HDL) and triglycerides
(p.0.05 in all analysis). In addition, the percentage of patients
taking lipid-lowering drugs increased from 12% to 26%
(p=0.042).
In the univariate logistic regression analysis, no factors were
associated with the development of dyslipidemia. Nevertheless, in
order to find a subset of variables that would account for the
development of dyslipidemia, a multivariate analysis (OR [95%
CI]) including all variables was performed. Only age was
associated with increased total cholesterol (OR=1.041
[1.016,1.067]), and HCV co-infection was found to be associated
Figure 3. Changes in fasting lipid profile in patients switched to DRV/r monotherapy in routine clinical practice (n=92).
Abbreviations: Total-c, total-cholesterol; HDL-c, high-density lipoprotein cholesterol; LDL-c, low-density lipoprotein cholesterol; TG, triglycerides; 95%
CI, 95% Confidence Interval.
doi:10.1371/journal.pone.0037442.g003
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[0.075,0.868]). There was no association between antiretrovirals
used before the switch to DRV/r and development of dyslipidemia
(Table 3).
Discussion
This study shows that simplification of ART with DRV/r
monotherapy in routine clinical practice is effective and well
tolerated in HIV-1-infected individuals with sustained viral
suppression. Although DRV/r monotherapy was also associated
with a significant increase in overall LDL-cholesterol levels, a
significant decrease in total cholesterol and triglyceride levels was
observed in patients with prior LPV/r. Therefore, with the
possible exception of patients with LPV/r-associated dyslipidemia,
DRV/r monotherapy does not seem to confer a clear advantage in
the routine management of dyslipidemia.
In the MONET study, DRV/r monotherapy was non-inferior
to DRV/r plus 2 NRTIs at 48 weeks in all analyses (per
protocol, intent-to-treat switch equals failure, and switch-included
analysis) [7]. However, at 96 weeks, DRV/r monotherapy
retained non-inferiority only in the switch-included and ob-
served-failure analyses, but not in the main switch-equals-failure
analysis [12]. In the MONOI study, non-inferiority to DRV/r
plus 2 NRTIs was only observed in the per-protocol analysis, but
not in the intention-to-treat analysis. The results of both analyses
were concordant for the magnitude of difference in efficacy
between arms, but discordant for the non-inferiority margin [8].
In our cohort, some baseline characteristics are different in
comparison to MONET and MONOI trials. Our cohort
included patients with slightly longer times since HIV diagnosis
and previous exposure to ART, a higher proportion of HCV-
coinfected patients, more heterogeneous treatment exposure with
more PI experience, and less NNRTI use at baseline than those
included in previous clinical trials [7,8]. Despite these differences,
the effectiveness rates of DRV/r monotherapy were similar to
those found in the MONET and MONOI studies [7,8]. At least
half of those patients with detectable viremia in our analysis
reported suboptimal adherence. In addition, as observed in
clinical trials [7,8], the development of virological failure to
DRV/r monotherapy in our cohort was not associated with the
loss of future therapeutic options, it was rarely associated with
resistance to PIs, and reintroduction of NRTIs achieved
virological suppression in all patients with virological failure.
Based on preliminary data suggesting a potential benefit of PI
monotherapy in the setting of NRTI-related toxicity [13,14], the
latest antiretroviral treatment guidelines from the International
Antiviral Society-USA (IAS-USA) and the European AIDS
Clinical Society (EACS) recognize PI monotherapy as an
alternative NRTI-sparing strategy if NRTI-related toxicity or
intolerance develops [3,4].
We found that DRV/r monotherapy was well tolerated: only 4
patients (4.3%) discontinued therapy owing to adverse events,
which were mostly gastrointestinal. Moreover, the significant
reductions in creatinine and alkaline phosphatase values observed
in these patients suggest that DRV/r monotherapy could
potentially improve TDF-associated kidney and bone toxicity.
Of note, lipid disorders associated to the use of ART could be
considered as toxic effect that leads to the use of PI monotherapy.
However, data on the effect of PI monotherapy on lipid profile are
scant. The most common laboratory abnormality observed in
patients using DRV/r monotherapy in the MONET study was an
increase in total cholesterol, particularly in patients who
interrupted TDF at baseline. Additionally, individuals starting
TDF in the triple therapy arm showed decreases in total
cholesterol [7]. Alongside other evidence [15–17], this has led
some authors to suggest a lipid-lowering effect of TDF. However,
is noteworthy that the increase in total cholesterol observed in the
MONET study was only observed in 8 patients (5 in DR/r
monotherapy group and 3 in triple therapy arm) [7]. So,
conclusions about the role of DRV/r monotherapy in the setting
of lipid disorders could not be properly provided.
We found initiation of DRV/r monotherapy to be associated
with a significant increase in LDL and total cholesterol levels, as
well as with an increase in the number of patients taking lipid-
lowering therapy. In agreement with MONET study, this was also
particularly evident in patients who withdrew TDF at baseline [7].
As previously reported [18–20], younger age and HCV co-
infection were associated with a decreased risk of developing
hypercholesterolemia in the multivariate analysis. On the other
hand, triglyceride and total cholesterol levels improved in patients
who switched from triple therapy regimens including LPV/r to
DRV/r monotherapy. These changes, however, were not reflected
in significant changes in the proportion of patients with
dyslipidemia according to the ATP III classification. Perhaps with
the exception of patients previously receiving LPV/r, our results
suggest that DRV/r monotherapy does not confer a clear
advantage in the management of metabolic disorders.
The main limitations are the relatively low number of patients
included, the retrospective design, which could lead to bias or
unmeasured confounding, and the lack of a comparative arm to
assess the magnitude of differences relative to continuing standard
ART. Currently, PI monotherapy, particularly with DRV/r, has a
defined use in highly selected patients, so large cohort studies are
difficult to perform. To our knowledge, there is only one large
ongoing long-term cohort study of patients with PI monotherapy
(Protease Inhibitor Monotherapy Versus Ongoing Triple-therapy
in the Long Term Management of HIV Infection (PIVOT).
Avalible at: http://clinicaltrials.gov, identifier NCT01230580),
but the communication of the results is not foreseen in short term.
Therefore, our study is the first to report the safety and virological
effectiveness of DRV/r monotherapy in routine clinical practice
and our findings provide insight into the advantages and
disadvantages, especially those related to metabolic effects of
using DRV/r monotherapy in daily clinical practice and, thus,
useful information for future clinical trials.
In conclusion, DRV/r monotherapy appears to be safe and
effective in HIV-1-infected patients with sustained viral suppres-
sion in routine clinical practice. However, with the possible
exception of patients previously receiving LPV/r, DRV/r
monotherapy does not seem to confer a clear benefit in the
management of dyslipidemia. Prospective controlled studies are
needed to elucidate the effects of DRV/r monotherapy on
cholesterol levels, as well as on the management of antiretrovi-
ral-related kidney and bone toxicity.
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